A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies

Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials

(2010) Piotr Rutkowski et al.   JOURNAL OF CLINICAL ONCOLOGY

Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor α in a subset of normal and systemic sclerosis patient sera

(2009) Nick Loizos et al.   ARTHRITIS AND RHEUMATISM

Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis

(2009) Jean-François Classen et al.   ARTHRITIS AND RHEUMATISM

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease

(2009) P. J. Martin et al.   BLOOD

Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease

(2009) L. Magro et al.   BLOOD

Imatinib for refractory chronic graft-versus-host disease with fibrotic features

(2009) A. Olivieri et al.   BLOOD

Skin response using NIH consensus criteria vs Hopkins scale in a phase II study for steroid-refractory chronic GVHD

(2009) D A Jacobsohn et al.   BONE MARROW TRANSPLANTATION

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

(2009) Arturo Vega-Ruiz et al.   LEUKEMIA RESEARCH

A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease

(2008) M. E. D. Flowers et al.   BLOOD

The Effect of Imatinib (Glivec®) on Scleroderma and Normal Dermal Fibroblasts: A Preclinical Study

(2008) A. Soria et al.   DERMATOLOGY

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib

(2008) Elizabeth Day et al.   EUROPEAN JOURNAL OF PHARMACOLOGY